Limited testing has demonstrated excellent correlation with both handheld commercial glucometers and sophisticated laboratory instruments well within the US Food and Drug Administration’s (FDA) required measurement tolerances.
This breakthrough could put pain-free glucose testing within the reach of every diabetic and practitioner.
The patent-pending sensor is formed using a small nanotechnology platform matched to widely accepted and FDA-approved common enzyme chemistry.
The enzyme is an oxido-reductase that catalyzes the oxidation of glucose, which is then sensed by the nanotechnology platform. Plans are underway to conduct broader clinical trials prior to seeking FDA approval as a screening and monitoring device.
NanoBio Systems is a technology development company pursuing innovative, proven applied engineering solutions to develop biochemical sensors for personal health care monitoring.
